SG Americas Securities LLC Has $311,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

SG Americas Securities LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 74.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,350 shares of the biotechnology company’s stock after selling 117,571 shares during the quarter. SG Americas Securities LLC’s holdings in BioCryst Pharmaceuticals were worth $311,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Principal Financial Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after buying an additional 375,890 shares in the last quarter. Exome Asset Management LLC bought a new position in BioCryst Pharmaceuticals during the 3rd quarter worth $1,493,000. Franklin Resources Inc. raised its holdings in BioCryst Pharmaceuticals by 177.8% in the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock valued at $1,968,000 after acquiring an additional 168,790 shares in the last quarter. Sanctuary Advisors LLC lifted its position in shares of BioCryst Pharmaceuticals by 78.3% during the 3rd quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company’s stock valued at $360,000 after acquiring an additional 20,818 shares during the period. Finally, SkyView Investment Advisors LLC grew its holdings in shares of BioCryst Pharmaceuticals by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BCRX. Evercore ISI boosted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Needham & Company LLC boosted their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Barclays boosted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.50.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $8.09 on Wednesday. The firm has a market cap of $1.68 billion, a P/E ratio of -13.26 and a beta of 1.75. The firm’s fifty day moving average is $7.65 and its 200 day moving average is $7.70. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.19) EPS. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.